Cipher Pharmaceuticals Stock Fundamentals
| CPH Stock | CAD 11.35 0.33 2.83% |
Cipher Pharmaceuticals fundamentals help investors to digest information that contributes to Cipher Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cipher Stock. The fundamental analysis module provides a way to measure Cipher Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cipher Pharmaceuticals stock.
At this time, Cipher Pharmaceuticals' Income Before Tax is very stable compared to the past year. As of the 15th of March 2025, Total Other Income Expense Net is likely to grow to about 1.1 M, while Depreciation And Amortization is likely to drop about 1.4 M. Cipher | Select Account or Indicator |
Cipher Pharmaceuticals Company Operating Margin Analysis
Cipher Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cipher Pharmaceuticals Operating Margin | 0.18 % |
Most of Cipher Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cipher Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cipher Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Cipher Pharmaceuticals is extremely important. It helps to project a fair market value of Cipher Stock properly, considering its historical fundamentals such as Operating Margin. Since Cipher Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cipher Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cipher Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Cipher Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Cipher Pharmaceuticals has an Operating Margin of 0.1803%. This is 100.51% lower than that of the Pharmaceuticals sector and 100.49% lower than that of the Health Care industry. The operating margin for all Canada stocks is 103.27% lower than that of the firm.
Cipher Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cipher Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cipher Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cipher Pharmaceuticals competition to find correlations between indicators driving Cipher Pharmaceuticals's intrinsic value. More Info.Cipher Pharmaceuticals is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cipher Pharmaceuticals is roughly 3.55 . At this time, Cipher Pharmaceuticals' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cipher Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cipher Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cipher Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cipher Pharmaceuticals from analyzing Cipher Pharmaceuticals' financial statements. These drivers represent accounts that assess Cipher Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cipher Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 19.7M | 37.2M | 304.5M | 106.4M | 95.8M | 69.3M | |
| Enterprise Value | 12.4M | 17.2M | 276.1M | 66.9M | 60.2M | 60.9M |
Cipher Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0506 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 343.74 M | ||||
| Shares Outstanding | 25.59 M | ||||
| Shares Owned By Insiders | 41.96 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 18.27 K | ||||
| Price To Earning | 21.55 X | ||||
| Price To Book | 2.09 X | ||||
| Price To Sales | 10.98 X | ||||
| Revenue | 21.16 M | ||||
| Gross Profit | 21.38 M | ||||
| EBITDA | 11.26 M | ||||
| Net Income | 20.38 M | ||||
| Cash And Equivalents | 9.25 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 353 K | ||||
| Debt To Equity | 62.30 % | ||||
| Current Ratio | 1.06 X | ||||
| Book Value Per Share | 3.86 X | ||||
| Cash Flow From Operations | 16 M | ||||
| Short Ratio | 0.45 X | ||||
| Earnings Per Share | 0.90 X | ||||
| Target Price | 16.7 | ||||
| Beta | 1.14 | ||||
| Market Capitalization | 290.44 M | ||||
| Total Asset | 86.03 M | ||||
| Retained Earnings | 66.27 M | ||||
| Working Capital | 43.02 M | ||||
| Net Asset | 86.03 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 467.1 K | 714.3 K | |
| Total Revenue | 24.3 M | 18.1 M | |
| Cost Of Revenue | 4.7 M | 2.7 M | |
| Stock Based Compensation To Revenue | 0.06 | 0.06 | |
| Sales General And Administrative To Revenue | 0.29 | 0.28 | |
| Research And Ddevelopement To Revenue | 0.02 | 0.02 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 0.75 | 0.49 | |
| Ebit Per Revenue | 0.49 | 0.51 |
Pair Trading with Cipher Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cipher Stock
Moving against Cipher Stock
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.